This announcement serves to conclude drug discount contracts in accordance with Section 130a (8) SGB V on the active substance (s) mentioned under point II.1.1). It is not about awarding public contracts within the meaning of Directive 2014/24 / EU or Sections 97 ff GWB. Any pharmaceutical entrepreneur can become a contractual partner in accordance with Section 4 (18) AMG. According to the case law of the CJEU, such approval procedures are not necessarily subject to public procurement law, since there is no competition due to the lack of a selection decision. The announcement serves as an invitation to conclude discount contracts with non-dispositional conditions that apply to all contractual partners, including the determination of the discount. The contract is concluded by signing the contract documents and submitting the required declarations, which can be requested from the contact point named under I.3).

The earliest start of the contract is 1.9.2020 if the signed contract and the required declarations have been received by the contact point named under I.3) by 10.8.2020. The information in IV.2.2) refers to this. In the event of late receipt, the contract begins on the 1st of the month, which follows the month of receipt of the signed contract and the required declarations or evidence at the contact point named under I.3), provided the receipt is received by the 5th of each month ; otherwise the 1st of the month after next. The contracts end automatically without the need for termination as soon as contracts are concluded for the active substance (s) or combination of active substances as part of an award procedure. The contracts end on August 31, 2022. The framework agreement can be extended once by the pharmaceutical company or by spectrumK for a maximum of 6 months.